Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes

Abstract

The disclosure provides a description of a tissue modulation device, for treating at least one of obesity, metabolic syndrome, and Type 2 diabetes in a patient. In some embodiments, the device includes a storage module having computer-readable instructions for delivering an electrical stimulation pattern to a splanchnic nerve of the patient. The stimulation pattern includes at least one on-time. The on-time includes at least one of a suprathreshold period and a subthreshold period. The splanchnic nerve is selected from the group consisting of the greater splanchnic nerve, the lesser splanchnic nerve, and the least splanchnic nerve. The pattern is effective to ameliorate at least one attendant condition of obesity, metabolic syndrome, and Type 2 diabetes in the patient. The attendant condition includes dyslipidemia, hypertension, hyperinsulinemia, hyperglycemia, and / or insulin resistance.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation-in-part application of U.S. patent application Ser. No. 11 / 338,388, filed Jan. 24, 2006, and entitled “Neural Stimulation for Treatment of Metabolic Syndrome and Type 2 Diabetes,” which is a continuation-in-part of U.S. patent application Ser. No. 10 / 920,734, filed Aug. 18, 2004, and entitled “Dynamic Nerve Stimulation for Treatment of Disorders,” which is a continuation-in-part of U.S. patent application Ser. No. 10 / 785,726, filed Feb. 24, 2004, and entitled “Splanchnic Nerve Stimulation for Treatment of Obesity,” now U.S. Pat. No. 7,551,964, which is a continuation in part application of U.S. patent application Ser. No. 10 / 272,430, filed Oct. 16, 2002, and entitled “Wireless Electric Modulation of Sympathetic Nervous System,” now U.S. Pat. No. 7,236,822, which is a continuation-in-part application of U.S. patent application. Ser. No. 10 / 243,612, filed Sep. 13, 2002, and entitled “Electric Modulation of...

AI Technical Summary

Benefits of technology

[0026]In certain embodiments, a method for treating at least one of obesity, Type 2 diabetes, and metabolic syndrome in a patient is disclosed. The method comprises providing a pulse generator, the pulse generator having a programmable stimulation pattern with a signal-on time that comprises a subthreshold period and a suprathreshold period. The method further comprises electrically activating a splanchnic nerve of a patient with the pulse generator, using the stimulation pattern, so as to ameliorate or eliminate an attendant condition of obesity, metabolic syndrome, and Type 2 diabetes in the patient. The attendant condition comprises at least one of dyslipidemia, hypertension, hyperinsulinemia, hyperglycemia, and insulin resistance, wherein the splanchnic nerve is selected from the group consisting of the greater splanchnic nerve, the lesser splanchnic nerve, and the least splanchnic nerve.

Problems solved by technology

Obesity results from an imbalance between food intake and energy expenditure such that there is a net increase in fat reserves.

Excessive food intake, reduced energy expenditure, or both may cause this imbalance.

Destruction of the lateral hypothalamus results in hunger suppression, reduced food intake, weight loss, and increased sympathetic activity.

In contrast, destruction of the ventromedial nucleus of the hypothalamus results in suppression of satiety, excessive food intake, weight gain, and decreased sympathetic activity.

In addition, drugs such as nicotine, ephedrine, caffeine, subitramine, dexfenfluramine, increase sympathetic activity and reduce food intake.

Sympathetic activity reduces gastric and duodenal motility, causes gastric distention, and can increase pyloric sphincter, which can result in distention and delayed gastric emptying.

Catecholamines and cortisol, which are released by the sympathetic nervous system, cause a dose-dependent increase in resting energy expenditure.

Drugs that activate the sympathetic nervous system, such as ephedrine, caffeine and nicotine, are known to increase energy expenditure.

Smokers are known to have lower body fat stores and increased energy expenditure.

Plasma levels can be achieved that cause increased energy expenditure.

However, these measures often fail and behavioral treatment is supplemented with pharmacologic treatment using the pharmacologic agents noted above to reduce appetite and increase energy expenditure.

Pharmacologic therapy is typically delivered orally and results in systemic side effects such as tachycardia, sweating, and hypertension.

These procedures can be very effective in treating obesity, but they are highly invasive, require significant lifestyle changes, and can have severe complications.

Neither of these therapies increases energy expenditure.

Each or these conditions is considered to be a risk factor for certain other diseases, however, combined together, these conditions indicate a significantly higher likelihood of developing a life threatening disease.

This may compensate for the insulin resistance for a while, but eventually, the pancreas can not keep up the levels of insulin necessary to maintain proper glucose absorption and, as a result, glucose accumulates in the body leading to Type 2 diabetes.

As the insulin resistance develops and glucose levels rise, the health risks associated with the high insulin levels begin to take effect.

Consistently high levels of insulin and glucose may cause a variety of negative effects such as damage to the lining of arteries which can lead to heart attack or stroke.

These abnormal levels can also cause changes in the ability of the kidneys to remove salt, leading to high blood pressure, heart disease and stroke.

Other consequences include an increase in triglyceride levels, which can lead to an increased risk of developing cardiovascular disease as well as a slowing of insulin production, which can indicate the onset of Type 2 diabetes, which in turn can cause heart attack, stroke, as well as damage to the eyes, nerves or kidneys.

Unfortunately, compliance is often a major shortcoming with regard to such a treatment regimen.

In general, any treatment regimen that involves dramatic lifestyle changes and daily medication runs the risk of low compliance.

In addition, some of the medications discussed above may have significant side effects that pose risks to the patient taking such medications.

Images